Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone OROS for Sleep Disturbance in Korean Cancer Patients
NCT00766831Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2008
- Primary completion
- Jun 2010
- Modality
- Orthosteric Ligands
01
Overview
Phase 4, open-label, single-arm trial of hydromorphone in cancer pain, sponsored by Janssen Pharmaceutical. Primary endpoint: Percentage of Treatment Response in Sleep Disturbance Caused by Cancer Pain at Day 15. Started Oct 2008; status: completed.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT00766831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00766831.